Tango Therapeutics Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended June 30, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from _____________ to _____________Commission File Number: 001-39485 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware85-1195036(State or other jurisdiction ofincorporation or organization)(I.R.S. EmployerIdentification No.)201 Brookline Ave., Suite 901Boston, MA02215(Address of principal executive offices)(Zip Code)(857) 320-4900(Registrant’s telephone number, including area code) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) hasbeen subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒Emerging growth company☐ Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of August 4, 2026, the registrant had 168,610,367 shares of common stock, $0.001 par value per share, outstanding. Table of Contents PART I.FINANCIAL INFORMATION Item 1.Financial Statements (Unaudited)Condensed Consolidated Balance SheetsCondensed Consolidated Statements of Operations and Comprehensive LossCondensed Consolidated Statements of Stockholders' EquityCondensed Consolidated Statements of Cash FlowsNotes to Condensed Consolidated Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and Procedures PART II.OTHER INFORMATION Item 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignatures Summary of Material Risks Associated with Our Business Our business is subject to numerous material and other risks that you should be aware of before making an investmentdecision with respect to our securities. These risks are described more fully in Part I, Item 1A of our Annual Report on Form 10-Kfor the year ended December 31, 2025 and this Quarterly Report on Form 10-Q. These risks include, among others, the following(which is not an exhaustive list of all such risks): •We are a precision oncology company with a limited operating history. We have no products approved for commercialsale, have not generated any revenue from product sales and may never become profitable. Further, we face substantialcompetition, which may result in others discovering, developing or commercializing products before or moresuccessfully than we do.•We have incurred significant net losses since our inception and anticipate that we will continue to incur losses for theforeseeable future. We expect our operating results to fluctuate significantly in the future as our business advances.•We will need to raise substantial additional funding. If we are unable to raise capital when needed or on termsacceptable to us, we would be forced to delay, reduce or eliminate some of our product development programs orcommercialization efforts. Raising additional capital may cause dilution to our stockholders, restrict our operations orrequire us to relinquish rights to our technologies or product candidates.•We have never successfully completed any clinical trials and we may be unable to do so for any product candidates wedevelop. Certain of our programs are still in preclinical development and may never advance to clinical development.•Our programs are focused on the development of oncology therapeutics for patients with genetically defined orbiomarker-driven cancers, which is a rapidly evolv